On June 3, 2025, IN8bio, Inc. announced a reverse stock split at a 1-for-30 ratio, effective June 5, 2025, following stockholder approval on May 8, 2025, reducing the outstanding shares from about 103 million to approximately 3.4 million. This adjustment will also affect stock options and the trading of common stock will begin on a split-adjusted basis on June 6, 2025.